Horehound (Marrubium vulgare L.): A Comprehensive Reference
1. Identity, Botanical Description, and Common Forms
Taxonomic Identity
Horehound (Marrubium vulgare) — commonly known as white horehound or common horehound — is a flowering plant in the mint family (Lamiaceae), native to Europe, northern Africa, and southwestern and central Asia. The qualifier "white" is generally used in botanical contexts to distinguish it from black horehound (Ballota nigra), a similar-looking but unrelated herb. The plant's formal designation in official pharmacopoeias is Marrubii herba, referring to the dried herb. White horehound consists of the dried leaves and flowering tops of Marrubium vulgare L., family Labiatae (syn. Lamiaceae). It is described in the British Pharmacopoeia/European Pharmacopoeia (BP/EP), the British Herbal Pharmacopoeia (BHP), and the Complete German Commission E monographs.
Etymology
The Latin name Marrubium derives from the Hebrew word marrob, meaning bitter juice, while vulgare means 'common' or 'well known'. In the English language, the name 'horehound' comes from the Old English words har and hune, meaning downy plant. The Oxford English Dictionary derives the word from Old English hoar (furry, as in "hoarfrost") and hune, a word of unknown origin designating a class of herbs.
Botanical Description
It is a grey-leaved herbaceous perennial plant that grows to 25–45 cm tall; the leaves are 2–5 cm long with a densely crinkled surface and are covered in downy hairs, while the flowers are white, borne in clusters on the upper part of the main stem. The plant has square stems, opposite lanceolate leaves with crenate margins, and dense terminal clusters of white, two-lipped labiate flowers.
Geographic Distribution
Native to Europe, northern Africa, and southwestern and central Asia, it emerged in the region between the Mediterranean Sea and Central Asia and now inhabits all continents, having been widely naturalized in most of North and South America. Small amounts are obtained commercially for medicinal purposes from southeastern Europe, Morocco, Italy, and France.
Common Names and Synonyms
The aerial parts and root of Marrubium vulgare have been traditionally used in Europe and in southern and eastern Mediterranean countries; during colonization, the plant was introduced to the Americas and became especially popular in Mexico and Brazil, where it has been known as 'maromba', 'marroio', or 'marroio-branco'.
Common Preparations and Dosage Forms
Commercially, horehound is included in herbal cough drops such as the Ricola brand, and is also available in powdered form or capsules, made into tinctures, syrups, cough drops, or hard candies. Horehound is now primarily used to flavor liqueurs, candies, and cough drops. The herb is also prepared as a tea or infusion. It has a very bitter taste, so it is often prepared with honey or other sweeteners.
2. Traditional and Historical Use
Ancient World: Egypt, Greece, and Rome
White horehound has been mentioned in conjunction with use as folk medicine dating at least back to the 1st century BC, where it appeared as a remedy for respiratory ailments in the treatise De Medicina by Roman encyclopaedist Aulus Cornelius Celsus. The Egyptians and the Greeks used it to treat respiratory problems, while the Romans used horehound as an antidote to poisons. Columella, a 1st-century Roman agricultural writer, stated that horehound was useful in treating worms in farm animals. Marrubium vulgare has been used as an expectorant since ancient Egypt; Egyptian priests referred to the plant as "Seed of Horus," "Bull's Blood," or "Eye of the Bull." Ancient Egyptian priests used it in ceremonial preparations, while Greek physician Dioscorides documented its use for chest complaints in the 1st century CE.
Middle Ages and Early Modern Europe
In the Middle Ages, horehound was thought to ward off evil spirits, and charms containing horehound were worn for protection. American Eclectic physicians — doctors who recommended herbs — of the 19th century remarked on its value as a medicinal plant not only for coughs and asthma but also in menstrual complaints. Horehound was reportedly first used in ancient Rome by the physician Galen, who recommended it as a therapy for coughs and other respiratory ailments.
Middle East and Hebrew Tradition
Horehound was important in Israeli and Arabic medicinal folk traditions; the Hebrew word for bitter juice is marrub, which could be a possible origin of horehound's botanical name, and some writers claim it was one of the bitter herbs used during Passover, though other writers dispute this.
South America and Mexico
Ethnopharmacological uses of M. vulgare in Latin America include treating respiratory diseases such as acute or chronic bronchitis, colds, and asthma; the plant is also used in cases of lack of appetite or dyspepsia and for diagnosed type 2 diabetes, and has even been used for antihypertensive therapy.
North Africa, the Middle East, and Iran
In North Africa (Algeria), Marrubium plants are used in folk medicine as expectorants and for their antispasmodic properties in acute or chronic bronchitis, coughs, asthma, and general respiratory infections; they are also used in cases of lack of appetite and dyspepsia. Marrubium vulgare is one of the medicinal plants used in the treatment of stomach complaints, arrhythmia, asthma, jaundice, lung diseases, and liver disorders in Iranian traditional medicine. In Tunisian folk medicine, horehound was used as a hypotensive, hypoglycaemic, and cardiotonic agent. In France, Pages and Comte (1927) described the traditional use of horehound as an antiarrhythmic.
Traditional Preparations
In 1954, Belgian literature ("Materia Medica Vegetabilis") illustrated the use of white horehound as a decoction with honey syrup against bronchitis and coughs. The herb was also prepared as expressed juice, infusions, syrups, and poultices. In Serbian folk tradition, tea from the herb was typically used as a bitter remedy by women who were unable to conceive, for regulation of the menstrual cycle.
Official Recognition of Traditional Use
M. vulgare has been described in monographs of the German Commission E as a treatment for colds, as a digestive, and as a choleretic. The EMA supports traditional use of M. vulgare as an expectorant in catarrh for a period not exceeding 7 days and in the treatment of dyspepsia symptoms such as swelling, flatulence, or temporary loss of appetite for a maximum of 2 weeks.
3. Phytochemistry: Key Constituents and Chemical Identity
Primary Diterpenoid Compounds
Marrubiin is a widely known diterpenoid lactone that constitutes the bitter principle of horehound and many other medicinal plants of the family Lamiaceae. It is characterized as a labdane diterpene specific to this genus, along with a complex mixture of phenolic compounds. Marrubiin, on the opening of its lactone ring, gives marrubiinic acid, to which is ascribed the choleretic property of the drug; related compounds present to a lesser extent are the diterpene alcohols marrubenol and vulgarol.
The secondary metabolites of M. vulgare include diterpenes, sesquiterpenes, flavonoids, and phenylpropanoids identified from different parts of the plant; marrubiin, marrubiinic acid, and marrubenol are the major diterpenes, which exhibit analgesic and antiedematogenic activities.
Flavonoids and Phenolic Compounds
Other constituents include ubiquitous flavonoids such as vitexin, apigenin, and luteolin together with their glycosides, and the alkaloids betonicine and stachydrine. The biological activity of horehound hydroethanolic herb extract derives from multiple chemical compounds, including polyphenols, flavonoids, phenolic acids, and tannins; chromatographic analyses of the extract identified 12 phenolic compounds, of which ferulic acid, catechin, quercetin, protocatechuic acid, rutin, and syringic acid were the main constituents.
Essential Oil Constituents
GC-MS analysis revealed that the major components of horehound essential oil are E-caryophyllene (35.7%), germacrene D (25.2%), and bicyclogermacrene (10.6%).
Phenylethanoid Glycosides and Other Compounds
Members of this genus are characterized by a wide range of bioactive secondary metabolites that include labdane-type diterpenes (notably marrubiin), phenylethanoid glycosides (such as verbascoside and forsythoside B), phenylpropanoids, flavonoids, and lignan derivatives. Horehound contains a number of constituents, including alkaloids, flavonoids, diterpenes (e.g., marrubiin), and trace amounts of volatile oils.
Biosynthesis of Marrubiin
Horehound is a medicinal plant whose signature bioactive compounds, marrubiin and related furanoid diterpenoid lactones, have potential applications for the treatment of cardiovascular diseases and type 2 diabetes. Young leaves and buds contain the highest content of furanic labdane diterpenes, which are mostly stored in peltate glandular trichomes.
4. Established and Proposed Mechanisms of Action
Expectorant and Mucolytic Action
The major active constituent in horehound is marrubiin, which is thought to be responsible for the expectorant — promotion of coughing up of mucus — action of the herb. In addition, marrubiin contributes to the bitter taste of horehound, an action that increases the flow of saliva and gastric juice, thereby stimulating the appetite; these actions likely explain the long-standing use of horehound as a cough suppressant and expectorant as well as a bitter digestive tonic. Marrubiin is known, above all, by its stimulating effects on secretions in the bronchial mucosa.
Choleretic Action
Marrubiin, on the opening of its lactone ring, gives marrubiinic acid, to which is ascribed the choleretic property of the drug. This mechanism — stimulation of bile flow — underlies the herb's traditional use as a digestive bitter.
Antinociceptive (Pain-Modulating) Action
Previous work had shown that M. vulgare exhibits antispasmodic and antinociceptive effects in different experimental models; marrubiin, the main constituent, showed potent and dose-related antinociceptive effects in animal models, with calculated ID₅₀ values of 2.2 μmol/kg in the writhing test, 6.6 and 6.3 μmol/kg (first and second phases) in the formalin-induced pain test, and 28.8 μmol/kg in the capsaicin test. The antinociception produced by marrubiin was not reversed by naloxone, and its exact mechanism of action remains to be determined, but results suggest that marrubiin does not interact with opioid systems.
Vasorelaxant and Cardiovascular Action
Research has revealed that marrubiin exerts vasodilator action via a combination of endothelium-independent Ca²⁺ antagonism and endothelium-dependent nitric oxide-modulating mechanisms; crude extracts of the aerial parts of M. vulgare showed appreciable in vitro inhibition of KCl-induced contraction of rat aorta, indicating vasorelaxant properties. Marrubiin has also been documented to exert anti-arrhythmic, antioxidant, vasorelaxant, antinociceptive, gastroprotective, antispasmodic, immunomodulating, anti-edematogenic, and analgesic effects.
Antioxidant Activity
The DPPH radical scavenging ability of horehound extract was 68.29%, and extract decreased the level of intracellular reactive oxygen species in fibroblasts and keratinocytes in vitro, achieving the strongest antioxidant effect at a concentration of 2.5% in both skin cell types. Potent antioxidant activity has been demonstrated and is most likely due to the phenolic compounds in the plant leaves; however, antioxidant activity varies depending on the type of organic solvent used for extraction and the sampling location.
Gastroprotective Action
The gastroprotective activity of marrubiin was established through in vivo analysis using protocols with ulcers induced by ethanol/HCl and indomethacin/bethanecol in mice; in both models, marrubiin at 25 mg/kg produced a significant reduction compared with the control group (p < 0.01).
5. Scientific Evidence by Area of Use
5.1 Respiratory System: Cough, Bronchitis, and Expectorant Use
The principal use of white horehound is as an expectorant and antispasmodic in the treatment of bronchitis and whooping cough; it also possesses choleretic properties. However, the human clinical evidence specifically confirming these respiratory effects remains sparse. Clinical studies regarding the therapeutic use of horehound are limited; most animal research has centered on the potential for use in cardiovascular disease, diabetes, pain and inflammation, and wound healing; however, little or no clinical evidence supports the use of horehound for any indication. The EMA's Committee on Herbal Medicinal Products (HMPC) assessed this evidence base and concluded that the evidence meets the threshold for traditional use classification rather than well-established use. The EMA supports traditional use of M. vulgare as an expectorant in catarrh for a period not exceeding 7 days. The HMPC concluded that, on the basis of its long-standing use, white horehound can be used, and that it should only be used in adults and adolescents aged over 12 years.
Evidence strength: The respiratory use of horehound is supported by long-standing traditional use, official European regulatory recognition under the traditional use pathway, and plausible pharmacological mechanisms in animal and in vitro studies. Controlled human clinical trials specifically confirming efficacy in cough or bronchitis are lacking.
5.2 Digestive System: Bitter Tonic and Dyspepsia
Throughout history, Marrubium vulgare extract has been recognized for its effects on digestive health; traditional European herbalists prescribed it for various gastrointestinal issues, including indigestion, bloating, and loss of appetite. Marrubiin contributes to the bitter taste of horehound, an action that increases the flow of saliva and gastric juice, thereby stimulating the appetite. The EMA supports its traditional use in dyspepsia symptoms such as swelling, flatulence, or temporary loss of appetite for a maximum of 2 weeks. Since horehound acts as a bitter and may increase production of stomach acid, people with gastritis or peptic ulcer disease should use it cautiously.
Evidence strength: Traditional use and regulatory recognition under the EMA traditional use pathway. Human clinical trial data specific to gastrointestinal effects are absent.
5.3 Diabetes (Type 2) and Hypoglycemic Activity
Early research suggests that drinking tea prepared from white horehound before meals, in addition to taking medication for diabetes, for 3 weeks slightly slowed blood sugar levels in people with type 2 diabetes. Horehound infusions prepared with the leaves of M. vulgare and administered in 1 g envelopes 3 times a day for 21 days were evaluated in one small clinical study of patients with type 2 diabetes receiving conventional treatment. This trial was designed for the evaluation of antidiabetic activity; however, the outcomes were contradictory to what previous in vivo mice assays had concluded, and the authors suggested a reevaluation of clinical trial methodology to establish valid and final results.
It is reported to have an antidiabetic and hypocholesterolemic effect in some studies. In animal models, in a study of an obese rat model, increased insulin secretion occurred with administration of marrubiin extracted from the related plant Leonotis leonurus; in rats with induced diabetes, an aqueous extract of M. vulgare was also investigated.
Evidence strength: Preliminary. One small human clinical trial yielded contradictory results. Animal and in vitro studies show promising but inconsistent hypoglycemic effects. Robust human clinical trials are absent.
5.4 Cardiovascular Effects: Antihypertensive and Cardioprotective
Limited studies in rodents suggest that marrubiin possesses anti-inflammatory and antioxidant activities which may be beneficial in reducing the effects of myocardial infarction; one group of researchers has demonstrated antihypertensive effects of a water extract of horehound in rodents. In an isoproterenol-induced myocardial infarction rat model, isoproterenol injection produced changes in ECG pattern including ST-segment elevation and suppressed R-amplitude; the methanolic extract of M. vulgare at doses of 10, 20, and 40 mg/kg significantly amended the ECG changes.
Evidence strength: Preclinical (animal) only. No human clinical trials have evaluated cardiovascular effects. Data from animal studies are suggestive but cannot be extrapolated to clinical recommendations.
5.5 Antimicrobial Activity
In screening studies, extracts of horehound and its essential oil have demonstrated activity against Helicobacter pylori and several other human bacterial and fungal pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Extracts from the horehound herb showed significant antimicrobial and anti-biofilm activity, confirming the plant's potential in therapeutic applications against various microbial pathogens (gram-positive and gram-negative bacteria and fungi). Its antimicrobial activity, especially against Gram+ bacteria, fungi, herpes simplex virus, and parasites such as Toxoplasma gondii, Trichomonas vaginalis, and Plasmodium berghei-berghei, was recorded.
Evidence strength: In vitro and animal studies only. No human clinical trials have assessed antimicrobial efficacy.
5.6 Antioxidant Properties and Potential in Chronic Disease
According to numerous studies, M. vulgare acts as a good antioxidant agent, and due to this, it could potentially be useful in treatments of cancer, diabetes mellitus, and liver diseases. A 2024 PMC study found a DPPH radical scavenging ability of 68.29%; M. vulgare extract decreased the level of intracellular reactive oxygen species in fibroblasts and keratinocytes in vitro, achieving the strongest antioxidant effect at a concentration of 2.5% in both skin cell types.
Evidence strength: In vitro. The antioxidant potential of horehound extracts is well documented in laboratory settings, but whether these translate to clinically meaningful benefits in humans has not been established.
5.7 Wound Healing
Natural healing mechanisms can be ineffective towards chronic or non-healing wounds; over the years, numerous studies have shown the great potential of plants in promoting wound healing, and research reports on the potential effect on wound healing of Marrubium vulgare, a medicinal plant known for several pharmaceutical activities. Its anti-inflammatory and wound-healing potential are among the properties discussed in the scientific literature.
Evidence strength: Preclinical (in vitro and animal) only. No controlled human wound-healing trials have been published.
5.8 Analgesic Effects
Marrubiin, a furane labdane diterpene, is the main analgesic compound present in Marrubium vulgare, a medicinal plant used in Brazil and other countries to treat several ailments. Structural modification to form marrubiinic acid and esterified derivatives exhibited significant analgesic effect in the writhing test in mice; marrubiinic acid showed better activity and excellent yield, and its analgesic effect was confirmed in other experimental models of pain in mice, suggesting its possible use as a model to obtain new and potent analgesic agents.
Evidence strength: Animal (preclinical) only. Analgesic effects are well characterized in rodent models but have not been assessed in human trials.
5.9 Lipid-Lowering (Hypolipidemic) Activity
Recent pharmacological investigations show that M. vulgare offers various in vivo and in vitro pharmacological activities including antihypertensive, antioxidant, anti-inflammatory, antidiabetic, effect on the respiratory system, digestive stimulant, antiasthmatic, hypolipidemic, antibacterial, and antifungal effects. The hypolipidemic properties have been explored primarily in animal models and in vitro systems.
Evidence strength: Animal/in vitro only. No human studies have assessed lipid-lowering efficacy.
Overall Assessment of the Evidence Base
Due to the numerous potentially beneficial properties identified in preclinical studies, there is a tendency toward the cultivation of M. vulgare to ensure high-quality raw material, but more firm scientific evidence and well-designed clinical trials are necessary for the well-established use of M. vulgare herb and its preparations. White horehound is a part of traditional medicine systems worldwide and is generally recognized as safe, but well-designed clinical trials are needed in order to shift from traditional to a well-established use of M. vulgare.
6. Dosage Forms and Reported Dosages
German Commission E Recommended Dosages
For adults, the German Commission E monograph recommends approximately 4.5 grams of horehound per day or 30–90 ml of the pressed juice. Alternatively, horehound tea can be prepared from approximately 1–2 grams of herb boiled in about 200 ml of water for ten minutes.
Clinical Trial Dosages
Horehound infusions prepared with the leaves of M. vulgare and administered in 1 g envelopes 3 times a day for 21 days were evaluated in one small clinical study of patients with type 2 diabetes receiving conventional treatment.
Animal Study Dosages (Preclinical Context)
In the isoproterenol-induced myocardial infarction rat model, treatment used 10, 20, and 40 mg/kg per 12 hours of the methanolic extract given orally. In gastroprotection models, marrubiin at 25 mg/kg produced significant results compared with controls. Animal dosages are provided for scientific context and cannot be extrapolated to human use.
EMA Traditional Use Duration Guidance
The EMA supports traditional use of M. vulgare as an expectorant in catarrh for a period not exceeding 7 days and in the treatment of dyspepsia symptoms such as swelling, flatulence, or temporary loss of appetite for a maximum of 2 weeks. Clinical trials are lacking to provide further dosing guidance.
7. Safety Profile, Contraindications, and Drug Interactions
General Safety and Regulatory Status
Although there is no evidence to support use in cough preparations from clinical trials, the FDA has granted horehound GRAS (Generally Recognized As Safe) status when consumed at concentrations used in such preparations. In phytotherapeutic books such as Bradley (1992), Blumenthal et al. (1998), and Blaschek et al. (2006), no adverse events, serious adverse events, or deaths are reported. In the BfArM (Germany) database, no adverse events are reported, and no adverse events were reported by other EU Member States during preparation of the EMA monograph.
Pregnancy and Lactation
Use in pregnancy is contraindicated; horehound reportedly has emmenagogue and abortifacient effects. Horehound should not be used during pregnancy, as it may stimulate contractions. Caution in pregnancy is advised because it may stimulate the uterus due to the volatile oils present.
Gastrointestinal Cautions
Since horehound acts as a bitter and may increase production of stomach acid, people with gastritis or peptic ulcer disease should use it cautiously.
Contact Dermatitis
In a list of occupational toxicity of cultivated flowers relating to the central states of the U.S., horehound juice is listed as a constituent that may induce contact dermatitis.
Drug Interactions: Tannin-Mediated Absorption Interference
Because of its high tannin content, decreased absorption of drugs co-administered with M. vulgare may occur; drugs should be taken at least 30 minutes before or after M. vulgare, and the same recommendation applies for minerals and thiamine.
Potential Interactions with Antidiabetic and Antihypertensive Drugs
The various extracts of this plant have shown pharmacological activities including antihypertensive, antispasmodic, analgesic, anti-inflammatory, hypolipidemic, hypoglycemic, vasodilating, antidiabetic, and antioxidant properties. Given these documented pharmacological activities in preclinical models, co-administration with antihypertensive or antidiabetic pharmaceutical agents carries a theoretical potential for additive or synergistic effects, though this has not been formally assessed in clinical studies.
Age Restrictions
According to the EMA's HMPC conclusions, white horehound should only be used in adults and adolescents aged over 12 years.
Adulteration Concerns
Two plants recognized as adulterants of Marrubium vulgare L. are Ballota nigra L. (black horehound) and Marrubium peregrinum L. (also called black horehound), which are morphologically similar to M. vulgare.
8. Body Systems and Health Areas Associated with Horehound
- Respiratory system: Ethnopharmacological uses include treating respiratory diseases such as acute or chronic bronchitis, colds, and asthma.
- Digestive system: The most prevailing traditional application of M. vulgare worldwide is for the treatment of gastrointestinal and respiratory disorders.
- Cardiovascular system: Marrubiin and related furanoid diterpenoid lactones have potential applications for the treatment of cardiovascular diseases.
- Metabolic/Endocrine (diabetes): The plant is also used in cases of lack of appetite or dyspepsia and for diagnosed type 2 diabetes.
- Pain/Inflammation: Pharmacological investigations show that the plant exerts anti-inflammatory, antiedematogenic, analgesic, antioxidant, antimicrobial, antidiabetic, cardiovascular hypolipidemic, and antispasmodic biological effects.
- Integumentary system (skin/wound healing): Research reports on the potential effect on wound healing of Marrubium vulgare, a plant known for several pharmaceutical activities.
- Antimicrobial/infectious disease: Extracts from the horehound herb showed significant antimicrobial and anti-biofilm activity against gram-positive and gram-negative bacteria and fungi.
References
Go back